Research

Vanderbilt, AstraZeneca collaborate on new COVID-19 antibody research

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.

Staph’s activation of blood clotting

Staph bacteria may change the factor they use to activate blood clotting — to evade the immune response — a new study suggests.

When rankings are unfounded

There are many good reasons to survey anesthesiology patient satisfaction but ranking individual clinicians isn’t one of them, the authors of a new study conclude.

Protecting the injured kidney

Leslie Gewin and colleagues have upended conventional dogma about Wnt/beta-catenin signaling in the kidney, finding that it protects against chronic kidney disease rather than promoting it.

Potential new cancer target

Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis.

Remdesivir helps reduce COVID-19 recovery time: study

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.

1 68 69 70 71 72 126